Local Health Units (ULS) in Portugal spent approximately 1,600 million euros on medicines, representing an increase compared to the previous period.
However, Infarmed, the medicines regulatory authority, indicates that during the first seven months of the year there was a slowdown in medicine spending, suggesting a trend of easing expenditure.
The therapeutic areas with the greatest impact on expenditure are oncology and HIV therapy, which consume a significant portion of the resources allocated to medicines.
This report comes in a context of concern about the sustainability of health spending and the continuous monitoring of costs associated with medicine treatments in the Portuguese health system.
